Pliant Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Pliant Therapeutics

08/11/2024 21:08

* Pliant Therapeutics Inc  PLRX.OQ  reported a quarterly
adjusted
loss of 95 cents​​ per share for the quarter ended September 30,
lower than the same quarter last year, when the company reported
EPS of -70 cents.  The mean expectation of twelve analysts for
the quarter was for a loss of 97 cents per share. Wall Street
expected results to range from $-1.15 to -87 cents per share.
    * Reported revenue was zero​; analysts expected $531.25
thousand. 
    * Pliant Therapeutics Inc's reported EPS for the quarter was
a
loss of 95 cents​.
    * The company reported a quarterly loss of $57.76 million.
    * Pliant Therapeutics Inc shares had risen by 35.5% this
quarter and lost 16.1% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 1.3%
in the last three months.​ 
    * In the last 30 days, two analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Pliant
Therapeutics Inc is $40.00 
This summary was machine generated from LSEG data November 8 at
09:08 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.97          -0.95          Beat
 Jun. 30 2024      -0.85          -0.92          Missed
 Mar. 31 2024      -0.77          -0.78          Missed
 Dec. 31 2023      -0.81          -0.69          Beat